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Summary: The enzymatic determination of the uric acid concentration in urine and serum according to Kageyama
((1971), Clin. Chim. Acta 31, 421—426), which excludes the deproteinization of samples, was adapted to the C4
automatic analyzer (Pefkin-Elmer). The reliability of this procedure and its correlation with an UV-method were
investigated. The interaction from-sample-to-sample was considerable, but this could be reduced by the addition of
Brij-35.
The recovery of uric acid added to protein-containing samples (about 96%) was better than with the UV-method.
Novaminsulfone was the only substance tested which interfered significantly.
Zuverlässigkeit eines mechanisierten Verfahrens (Perkin-Elmer C4) für die enzymatische Bestimmung von Harnsäure
nach Kageyama
Zusammenfassung: Die enzymatische Bestimmung der Harnsäure Konzentration nach Kageyama ((1971), Clin. Chim.
Acta 31,421^426) wurde an das Analysengerät C4 (Perkin-Elmer) adaptiert und deren Zuverlässigkeitskriterien unter-
sucht. Die Verschleppung von Probe zu Probe war beträchtlich, konnte jedoch durch Zusatz von Brij reduziert werden.
Zusatzversuche von Harnsäure mit proteinhaltigen Proben ergab eine höhere Wiederfindung (um 96%) als mit einer
vergleichenden UVJMethode. Bei einer Reihe von getesteten Substanzen führte nur Novaminsulfon zu einer signifi-
kanten Interferenz.
Introduction
Kageyama reported recently (1) a new procedure for the
direct enzymatic measurement of the uric acid concen*
tiation in urine and serum. This method uses the
Hmtzsch* reaction to determine formaldehyde formed
from uric acid by means of the two enzymes unease
(EC 1.7.3.3) and catalase (EC 1.11.1.6). The resulting
color (3,5-diacetyl-l,4-dihydrolutidine) has its absorb-
ance maximum at 410 nm.
This procedure appeared to be suitable for the mechanic
zation with a discrete analytical system. For this purpose
we used the Perkin-Elmer C4 Automatic Analyzer, a
combined-discrete system (2), since the reaction mixture
is transported in single cups and then transferred into a
discontinuous flow system for the photometric measure-
ment.
In the following investigations on the reliability of the
Kageyama method adjusted to the C4 analyzer are
reported. The direct enzymatic UV-procedure ofPrae-
torius (3) was chosen as the reference and performed
manually because we did not succeed in adapting this
method to the C4 analyzer with sufficient precision. A
sample blank assay treated with a glycerol solution in-
stead of the unease suspension was used according to
Kortum(4).
Methods and Materials
Operation of the C4 Automatic Analyzer
The analyzer ist operated according to the instructions of Perkin-
Elmer as shown in figure 1. The incubation time is 43 minutes at
37 °C. Sample batches are divided in 3 different segments as indi-
cated in figure 2. The inter-segment B can be repeated as often
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4. Uric acid stock standard, 5 mmol/1. This solution is prepared
according to Liddle et al. (5), chloroform is used as preserva-
tive (6).
Uric acid, dried 840.6 mg Merck No. 814
Bidist. H2O(60-80°C) 500ml
Li2CO3 1 g/100 ml:60-80°C) 50 ml







Fig. 1. Adaptation of the C4 Automatic Analyzer for the uric
acid determination.
as required. The concentration factor is calculated from the first
standard samples in segment A and introduced into the control
unit. The printed values of the standard solutions in B and C
segments are corrected directly with the factor potentiometer if
necessary. Blanks (bidist. H2O) can be omitted between 3 B seg-
ments. Urine samples (50 μΐ) are diluted with bidist. water
(500 μΐ) using Eppendorf pipettes.
Solutions
1. Colour reagent:
(NH4)2HP04 (757 mmol/1 100 g
H3P04, 85% (ca 44 mmol/1) 3 ml
CH3OH (ca. 2.47 mol/1) 100 ml




Bidist. H2O ad 1000 ml
2. Blank reagent: as solution (1) without uricase. Colour and
blank reagent are filtered (Selecta filter No. 595 1/2, Schlei-
cher and Sch ll, D-3354 Dassel).
Both solutions are stable for 10 days at 4°C according to I.e.
(1). The pH value of both colour and blank reagent is about
7.4 and is not adjusted to 7.0 as proposed by Kageyama (1).















This solution is stable for 1 month at 49C.
5. Uric acid working standard, 500 μηιοΐ/ΐ:
Uric acid stock standard 10 ml
140)3 lg/100 ml 5 ml
Bidist. H2O to 100 ml
This solution is prepared each day.
Other materials were purchased from E. Merck AG (D-6100
Darmstadt), bovine albumin (purest, dried) from Behring AG
(D-3550 Marburg) and Seronorm from Dr. Molter GmbH
(D-6900 Heidelberg).
The uricaquant test (Boehringer Mannheim, No. 15865) was
performed according to the instructions of the manufacturer.
For the direct enzymatic determination of the uric acid concen-
tration at 293 nm the Bpehringer test combination No. 15986
and a Zeiss PM 4 spectrophotometer were used. All results were
referred to the working standard solution (5).
The interaction from low to high concentrations (Qi) and from
high to low concentrations (Q2) was determined as recently
reported (7) and expressed as the percent interaction coefficient
(Q = 100 X q; for the explanation of q see Fig. 2).
The recovery of uric acid added to various samples was calcu-
lated from the results of the following assays:
1. 9.0 ml Li2CO3 solution (500 mg/1) + 1.0 ml stock standard
(5 mmol/1 uric acid);
2. 9.0 ml serum + 1.0 ml stock standard; and
3..9.0 ml serum + 1.0 ml Li2CO3 solution (500 mg/1).
Statistical evaluation of precision data were performed according
to Lc. (10).
Results and Discussion
Under our test conditions, the absprbance of the reac-
tion mixture slowly increased even in the absence of
uric acid (fig. 3). Precision therefore depends upon exact












20 samples AA AAA 20 sample
Interaction
q -. XA-XS. .X3 "X4
Qoao
Fig. 2. Sequence of samples introduced into the C4 Automatic Analyzer for the uric acid determination.
A: adjustment of the corresponding potentiometer if necessary. At F the concentration factor is calculated from the 4 pre-
ceeding values and introduced into the control unit. CZD Blank (H2O) ·1 Standard resa Control.
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Fig. 3. The reaction rate of the uric acid determination according
to Kageyama at 410 mm and 37° C (Zeiss photometer
PM 4 with automatic cuvet changing device). Cuvet 1:
picric acid solution for automatic correction of E = O.
Cuvet 2: 2500 *ii reaction solution (rs)+200 μΐ uric acid
solution (500 μηιοΐ/ΐ); cuvet 3: 2500 μΐ blank solution
(bs)+200 μΐ uric acid solution (500 μηιοΐ/ΐ); cuvet 4:
2500 μΙ rs + 200 μΐ bidist. H2O; cuvet 5: 2500 μΐ rs +
200 μΐ Monitrol I; cuvet 6: 2500 μΐ bs + 200 μΐ Moni-
trol I. The reaction was started by adding the sample as
indicated by the arrow.
timing. This can easily be achieved by using an analyzer
which transfers the prepared samples to the photometer
in the same time sequence as it starts the reaction.
Precision
The precision of the mechanized procedure is summa-
rized in table 1. The requirements of the College of
American Pathologists (precision from day to day: co-
coefficient of variation < 4.6%) and the Guidelines of
the Bundes rztekammer for Statistical Quality Control
and Collaborative Surveys (precision from day to day:
coefficent of variation < 10%) have been satisfied (9,10).
Accuracy
The detection limit calculated according to Kaiser (8) is
18 μτηοΐ/ΐ. The calibration curve is nearly linear up to a
concentration of 1500 μτηοΐ/ΐ (fig. 4). A sufficient corre-
lation was found when the uric acid concentration of
Tab. 1. The precision of the enzymatic determination of uric acid






Fig. 4. Calibration curve of the uric acid determination according
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Fig. 5. The correlation of the uric acid concentration in serum
samples from 70 patients determined according to Kage-
yama (1) and with an UV-method: y = 0.99 χ + 0.56
(r = 0.99).
serum and urine samples from several patients were deter-
mined with this and with a direct UV-rnethod (fig. 5 and
6). Recovery studies with pooled urine and serum samp-
les are summarized in table 2. For recovery studies it
appeared necessary to add albumin to the standard solu-
tion (70 g/1). Otherwise approximately 96% of the uric
acid added were recovered (tab. 2). This effect was in-
fluenced by the protein (tab. 3) and the uric acid concen-
tration (tab. 4); it was more pronounced with the UV-
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Uric odd (UV-method) Ιμπιοΐ/ΐ]
6000
Fig. 6. The correlation of the uric acid concentration in urine
samples from 80 patients determined according to
yama (1) and with an UV-method: y = 1.03 χ + 5.59
(r =0.99), η = 79.
Tab. 3. The influence of albumin on the uric acid concentra-
tion. Purified human albumin was added to a primary
standard solution of uric acid (500 μιηοΐ/ΐ). Each value































Tab. 4. The recovery of uric acid from aqueous solutions con-
taining bovine albumin (135 g/1) in relation to the uric
acid concentration. Each value (μηιοΙ/1) is a mean of
3 determinations.
Uric acid concentration (C4 analyzer)













Tab. 2. Recovery of uric acid added to various human serum
and urine samples. Each value (/imol/1) is a mean of at
least 2 determinations.
Sample Uric acid Recovery
added found
[μηιοΐ/l] ΙμπιοΙ/11 [%]
A) Calibration with a standard solution containing 70 g/1 albumin
Serum 500 499 99.8
Serum 314 313 99.7
Serum 291 291 100.0
Serum 321 320 99.7
Serum 493 490 99.4
B) Calibration with a protein-free standard solution
Urine 489 489 100.0
Urine 488 492 100.8


















































method (tab. 3) and can probably be explained by the
urate binding capacity of albumin and other serum pro-
teins (11,12,13). When primary standard solutions are
used for the calibration the results only correspond to the
unbound part of the total uric acid concentration in
serum.
With uricaquant, a commercially available test combi-
nation for the Kageyama procedure, the same results
were obtained if the test was performed either with a
C4 analyzer or manually following the instructions of
the manufacturer (tab. 3).
Serum samples can be stored in a refrigerator (+ 4°C) for
at least one week. During this time the uric acid concen-
tration is fairly stable (tab. 5).
Tab. 5. The stability of uric acid in human sera and urines if
stored at 49C.
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Drift effects
As recently pointed out (2) drift- and interaction effects
must be carefully investigated with fully mechanized
analytical methods. Baseline- and sensitivity drift (2)
between 20 samples were determined in segment A
and C (Fig. 2) of several batches on different days. The
sensitivity drift was less than 1% (tab. 6), if measured
with a concentration from the middle of the linear part
of the calibration curve (2). The baseline drift need not
be observed in every batch because it has the same value
as the sensitivity drift (tab. 6).
Tab. 6. Drift effects in segment A and C (1 intersegment B).
The numbers are means (μηιοΐ/ΐ) from several determi-
nations on different days. The calculation of the daily
value occurred as shown in Fig. 2. The sensitivity drift
was investigated with a standard containing 500 μιηοΐ/ΐ





I 2.7 1 (n = 17)
1 2.8 1 (n = 19)
C
I 2.7 I (n = 17)
1 2.9 I (n = 14)
Interaction effects
From a theoretical standpoint 2 types of interaction are
possible with the C4 Automatic Analyzer. A cyclic inter-
action (2) could not be detected when investigated ac-
cording to the recently reported method for the deter-
mination of chloride (7), using a solution with 2000
μτηοΐ/l uric acid and 7 g/100 ml purified albumin. The
interaction from sample-to-sample was considerable
and more pronounced in the presence bf protein (tab. 7).
The addition of Brij-35 reduced the carry-over signifi-
cantly (tab. 7).
Several procedures have been proposed (2) for the cor-
rection of all results by means of an interaction coeffi-
cient determined at the beginning of each batch from
a series of 3—4 interaction standards. The coefficient
of interaction varies considerably, even if determined
serially (tab. 7). Therefore, a mean value of several
determinations is preferable for the correction of all
batch results.
It is common practice to neglect carry-over effects if
the data cannot be processed by a computer. Since the
interaction from sample-to-sample of the mechanized
procedure was considerable (tab. 7), it was necessary to
determine whether the effect on the results was sufficient
to warrant correction. For this purpose, we postulate
that the difference between the true and the observed
value shall be lower than the Sfold standard deviation
of the corresponding mean value from several intrabatch
determinations (tab. 1). Then, in extreme cases the result
can differ approx. 3% from its true value in the normal
range of the human serum concentration. Using a pro?
cedure recently described (7) the concentration range,
in which interaction effects can be tolerated, was calcu-
lated (fig. 7). The analysis of a sample must be repeated
if the preceding value is outside the so called interaction-
safe range (fig. 7) or higher than 1000 μτηοΐ/ΐ.
Tab. 7. The interaction from sample to sample in the enzy-



























Q2x (%), s (n)
2.5 ± 0.4 (10)
2.5 ± 1.0(18)
4.5 ± 1.7 (12)





Fig. 7. Concentration range in which interaction effects can be
tolerated with the C4 Automatic Analyzer.
The concentrations forming the interaction-safe range are
calculated according to (7): Cl, / for the interaction from
low to high concentrations and C2, / for the interaction
from high to low concentrations. The standard deviations
are taken from table.1, the Q values from table 4 (last
line).
Tab. 8. The influence of ascorbate and bilirubin on the determi-




















1) mean value of 2 determinations
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Interferences
Interference from bilirubin, triglycerides and ascorbate
can be neglected with the determination of uric acid
according to Kageyama (1) under the present conditions
(tab. 8). Further studies were undertaken with a series of
drugs representing the most common therapeutics used
in human medicine (tab. 9). This list, in which the trade
name mentioned may be considered as an example for all
other drugs containing the same substance, was recom-
mended by Staehler et al. (J4). All substances were
added in 10 ml 9 g/1 NaCl to 40 ml of the same pool-
serum. These samples were analyzed in various series to-
gether with several control samples (10 ml 9 g/1 NaCl
+ 40 ml pool-serum). In the presence of tetracyclinum
and methyldopum the uric acid concentration was deter-
mined slightly below the 2s-range (tab. 8); this effect
could not be confirmed in further experiments. Nova-
minsulfone was the only substance which caused a con-
sistent underestimation of the uric acid concentration
(tab. 10). The oral intake of 6 mg/kg novaminsulfone
(Vs of the maximal dosage per day) leads to a serum
concentration of 14 mg/1 (16).
Tab. 9. Recovery of uric acid in human pooled sera containing
various drugs. In the absence of any substance added a
mean value of 239 μπιοΐ/ΐ uric acid was found (n = 43,
s = 10.91, 2s - range = 217-261).
Trade name I. N. N.a) concen- uric acid
tration
[mg/1] [Mrnol/1]
Glifanan glafeninum 240 222
Aspirin acidum acetylosalicylicum 600 243
Butazolidin phenylbutazonum 120 250
Novalgin novaminsulfonum 800 140b)
Buscopan hyoscin-N-butylbrominum 12 243
Amuno indometacinum 30 221
Dolviran acidum acetylosaiicyli- 480 251
cum, etc.
Prolixan 300 azopropazon-dihydrat 360 241
Actol acidum nifluminicum 150 232
Tanderil oxyphenbutazonum 120 257
Metalcaptase D-penicillaminum 480 234
Zyloric allopurinolum 80 251
Uricovac benzbromaronum 20 259
Benemid probenecidum 200 230
Lanicor digoxinum 0.15 217
Intensain carbocromenum 90 237
Novadral norfenefrinum 6 245
Miroton glycosides, etc. 6 ml/1 248
Aldaktone spirolactonum 20 222
Sembrina a-methyldopum 320 208b)
Modenol thiabutazide, etc. 2.6 254
Dipar phenylethylbiguanide 30 238
Euglycon glibenclamidum 3 234
Rastinon tolbutamidum 400 240
Solu-Decortin prednisolonum 200 233
Aponal doxepinum 30 228
Librium chlordiazepoxidum 20 228
Trade name I. N. N.a) concen- uric acid
tration
[mg/11 [μιηοΐ/ΐ]
Methotrexat acidum methylpteroyl- 1 237
glutaminicum
Endoxan cyclophosphamidum 40 227
Megaphen phenqthiazinum . 30 217
Luminai acidum phenylaethylbarbi- 80 220
turicum
Hostacyclin tetracyclinum 200 212°)
Paraxin cnloramphenicolum 600 217 )
Binotal aminobenzylpenicillinum 600 240
Sulfa- - sulfametum 300 237
Furadantin
Furadantin nitrofurantoinum 30 229
Durenat sulfanilarnidopyrimidinum 200 236
Refobacin gentamycinum 6 242
Lasix furosemidum 20 221
Dulcolax bisacodylum 4 244
Angiograiin acidum trijodbenzoicum 4 ml/1 253
Urografin acidum trijodbenzoicum 4 ml/1 246
Biligrafin adipinyltrijpdanilidum 4 ml/1 223
Resochin chloroquinum 100 243
Polybion Vitamine B complex 0.8 ml/1 241
Nicobion nicotinamidum 40 246
Cebion acidum ascorbicum 400 229
Marcumar phenprocoumonum 6 236
Macrodex dextrajuim 6% lOOml/1 246
Neoplasmagel gelatine 6% 100 ml/1 247





Dura-Clofibrat clofibratum 400 217
Antistin antazolinum 160 234
a) international non-proprietary names as proposed by the
WHO (15).
) this value is outside the 2s-range,
Tab. 10. The effect of novaminsulfone on the uric acid concen-
tration determined according to Kageyama in aqueous
solutions.
novaminsulfone uric acida) % of control
(in the absence of
I mg/1] [Aimol/1] novaminsulfone)
A) aqueous solutions
0 500








a) mean values of 2 determinations
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